Full-Time
Senior Inside Sales Representative
Revvity
1,001-5,000 employees
Translational multi-omics and diagnostics provider
Compensation Overview
$60k - $70k/yr
New Mexico, USA + 38 more
More locations: Washington, USA | Kansas, USA | Pennsylvania, USA | Oregon, USA | Delaware, USA | California, USA | Washington, DC, USA | Vermont, USA | Texas, USA | Montana, USA | Jackson Township, NJ, USA | Florida, USA | Waterbury, CT, USA | Nevada, USA | South Carolina, USA | South Dakota, USA | Georgia, USA | Arizona, USA | Concord, NH, USA | Tennessee, USA | Virginia, USA | Minnesota, USA | Colorado, USA | Nebraska, USA | Rhode Island, USA | Utah, USA | Kentucky, USA | New York, NY, USA | Maryland, USA | Maine, USA | Massachusetts, USA | North Carolina, USA | Oklahoma, USA | Missouri, USA | Ohio, USA | Indiana, USA | Michigan, USA | Illinois, USA
Remote
Must work Eastern Time business hours; occasional Saturday coverage may be required.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Revvity
See people who can refer or advise you
- Bachelor’s Degree
- A minimum of 5 years of sales experience
- Achieve daily, weekly, and monthly sales goals.
- Document and track all leads, contacts, opportunities, and activity history consistently and in accordance with best practices within Salesforce.com
- Manage and maintain a detailed pipeline to achieve assigned monthly quota.
- Contact existing client base to gain referrals and offer additional service options.
- Demonstrate technical capacity to understand sales tools (Web, database, CRM, Order Management, reports).
- Be able to effectively articulate technical and/or clinical information in an easily understood manner.
- Master product information for accurate dissemination to clients.
- Educate prospective customers on the value of newborn stem cell banking and other services provided by ViaCord.
- Comply with assigned schedules (including on-call rotation), assignments, and productivity metrics.
- Working Conditions: The primary working condition associated with this position is working independently in the office environment.
- Mental and Physical Demands: Requires the ability sit and/or stand for prolonged periods of time in a cubicle. Requires effective management of conflict and emotional or stressful situations.
- 3+ years of direct selling in a B2C (business to consumer) environment.
- Formally trained in a selling methodology (e.g., Consultative, SPIN, Challenger, etc).
- Strong analytical skills complimented by a successful track record in sales.
- Bi-lingual in either Spanish or Chinese a plus but not required.
- Self-motivated to exceed goals and ability to thrive in a team environment.
- Ability to create a sense of urgency and the follow-up skills to close sales.
- Articulate and professional with an enthusiastic attitude and a focus on results.
- Experience in a fast paced, inbound/outbound call environment is strongly desired.
- Strong interpersonal, written, phone and listening skills.
- Superior time management, planning and organizational skills
Revvity provides health science solutions that span the full journey from discovery to development and from diagnosis to cure. It offers translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics, all delivered as integrated workflows and expert services. The company differentiates itself with an end-to-end platform that combines omics, imaging, biomarkers, and data analytics with specialized support to speed development. Its goal is to turn previously impossible healthcare outcomes into achievable results, advancing discovery, development, diagnosis and patient care.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2023
Get referred to Revvity
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $730 million, and guidance rose after the beat.
- SuperFlex launched August 10, 2026, opening preeclampsia screening in lower-volume labs.
- T-SPOT A201 targets late 2027 launch, expanding Revvity's high-throughput infectious disease franchise.
What critics are saying
- Signals software revenue fell 20% in Q2 2026, weakening Revvity's premium mix.
- China Immunodiagnostics closing slips to 2027, leaving 6% revenue exposed longer.
- A failed diagnostics pivot leaves Revvity boxed into commoditized instruments and slower software growth.
What makes Revvity unique
- Revvity spans prenatal, TB, and R&D software workflows across 160 countries.
- SuperFlex and T-SPOT A201 target decentralized and high-throughput labs together.
- Signals AI with Claude embeds governed scientific data into researchers' daily workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 4%Revvity has launched the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed for laboratories and clinics with lower-volume workflows. The system tests for preeclampsia, which affects 2% to 8% of pregnancies globally. The platform features affordable instrument costs with annual maintenance, no reagent wastage at low volumes, and delivers results in as little as 14 minutes per test. It includes a test menu for first- and second-trimester biochemical prenatal screening. The system will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. Revvity reported 2025 revenue of $2.9 billion and employs approximately 11,000 people.
Upstart, an AI-powered lending platform, stands out as a buy opportunity among profitable stocks, according to StockStory's analysis. The company uses machine learning to assess borrower risk for various loan types. Upstart's loan originations surged 54.3% over the past year, enabling increased fee collection and expansion into new markets like credit cards. The company's revenue is expected to grow 30.6% over the next 12 months, with free cash flow anticipated to turn positive next year. Meanwhile, StockStory advises caution on Revvity and Northern Trust. Revvity's sales declined 10.6% annually over five years, whilst Northern Trust's 6.9% annual revenue growth lagged behind financial peers. Both companies face headwinds despite maintaining profitability, with earnings pressures and market share concerns affecting their outlooks.
Revvity reported second quarter 2026 revenue of $730 million, with pro forma revenue of $711 million representing 4% growth and 3% organic growth. The company posted GAAP earnings per share from continuing operations of $0.48, while adjusted EPS reached $1.41. The company announced a definitive agreement to divest its China Immunodiagnostics business, which accounted for approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals. Adjusted operating profit margin improved to 28.9%, up from 26.6% in the prior year period. GAAP operating income included $16 million in tariff-related refunds. Revvity raised its full-year guidance following the results.
A meaningful gift marks a milestone moment at Rompa CZ. Rompa now has a lasting reminder of the opening ceremony for its new Class 7 cleanroom facility in the Czech Republic, in the form of a thoughtful symbolic gift from its customer, the biotechnology company Revvity. This special artwork connects the event to the wider story of Life Sciences research, and was presented by Revvity's Managing Director, Jochem Bruggeman, to Marcos Valladolid, Rompa's COO. The story behind the artwork. The art was created using Revvity's own instruments and depicts HeLa cells, which hold a unique place in biomedical research. They were the first human cells successfully grown continuously in a laboratory and remain one of the most widely used cell lines in science today. Originally taken from Henrietta Lacks in 1951, HeLa cells have contributed to thousands of scientific breakthroughs over more than 75 years of research. They have played an important role in areas including vaccine development, cancer research, virology, drug screening, gene mapping and many other fields of biomedical science. The story of HeLa cells is also an important reminder of the ethical responsibilities that come with scientific progress. Henrietta Lacks' cells were used without her knowledge or consent, raising questions about patient rights, informed consent and the use of biological materials in research. Those discussions continue to influence how biomedical research is conducted today. Celebrating a long-standing partnership with Revvity. For Rompa, the present is a symbol of the partnership between its two companies and of the Life Sciences work now taking place inside the new cleanroom. The gift also marks Rompa's longstanding partnership with Revvity, whose products are among the first being produced in the new ISO Class 7 cleanroom at Rompa CZ. This made the opening ceremony not only a celebration of a new facility, but also a celebration of the collaboration, trust and shared commitment that helped bring the project to life. The cleanroom is designed to support multiple integrated production lines, including automated manufacturing solutions for microplate production. It enables Rompa to support customers with demanding applications in healthcare, diagnostics and other highly regulated Life Sciences markets. Rompa Group is grateful to Revvity for such a thoughtful gesture, and to everyone who joined Rompa Group to mark this important moment for Rompa CZ. As the artwork reminds Rompa Group, progress in Life Sciences depends on precision, partnership and respect for the scientific work that helps improve lives. Rompa Group is proud that its new cleanroom will play a part in supporting that work for years to come.
Revvity developing large scale latent tuberculosis test. * July 24, 2026 Revvity has announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB testing for large-volume clinical laboratories, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and broader public health programs. It is crucial for laboratories to deliver accurate results upon initial testing, while managing a high volume of samples to support timely treatment and improved patient outcomes. Building on the success of the Auto-Pure 2400 liquid handler, (pictured) the T-SPOT A201 platform is engineered to meet the throughput requirements of large-scale testing environments, strengthening the Revvity's automation portfolio and its ability to support laboratories across a range of throughput needs. It can process up to 384 samples per instrument in an 8-hour shift, with 45 seconds per sample of hands-on time - the lowest of any T-SPOT automation solution. The platform aims to ensure that these laboratories benefit from the scalability and workflow advantages associated with automated T-SPOT.TB testing. "The T-SPOT A201 automation platform represents a significant step forward in making the benefits of T-SPOT.TB testing accessible at scale," said Steven Hart, Vice President and General Manager of Infectious Disease Diagnostics at Revvity. "Our development program is focused on delivering a solution that gives high-volume clinical laboratories the performance, workflow efficiency, and competitive economics they need." The T-SPOT A201 platform is currently under development and targeted for launch in the second half of 2027, subject to regulatory approval.